id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2529-0008,FDA,FDA-2016-E-2529,"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL SOLUTION, New Drug Application 205838",Notice,Determinations,2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,2020-02-11T04:59:59Z,2019-12-12T14:38:30Z,2019-26814,0,0,0900006484206b7a
FDA-2016-E-2529-0007,FDA,FDA-2016-E-2529,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T17:15:39Z,,0,0,0900006484115a24
FDA-2016-E-2529-0005,FDA,FDA-2016-E-2529,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2018-10-01T18:53:08Z,,0,0,0900006483788b2d
FDA-2016-E-2529-0006,FDA,FDA-2016-E-2529,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-01T04:00:00Z,2018,10,2018-10-01T04:00:00Z,,2018-10-01T18:57:54Z,,0,0,0900006483788bb4
FDA-2016-E-2529-0004,FDA,FDA-2016-E-2529,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-01-19T05:00:00Z,2017,1,2017-01-19T05:00:00Z,,2017-01-19T12:54:19Z,,0,0,09000064824842c1
FDA-2016-E-2529-0003,FDA,FDA-2016-E-2529,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-09-26T04:00:00Z,2016,9,2016-09-26T04:00:00Z,,2016-09-26T16:23:58Z,,0,0,090000648226830b
FDA-2016-E-2529-0001,FDA,FDA-2016-E-2529,"Patent Extension Application from Harness, Dickey & Pierce P.L.C. (on behalf of UCB Biopharma SPRL)",Other,Application,2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T19:02:36Z,,0,0,0900006482198c9a
FDA-2016-E-2529-0002,FDA,FDA-2016-E-2529,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-08-24T04:00:00Z,2016,8,2016-08-24T04:00:00Z,,2016-08-24T19:02:45Z,,0,0,0900006482198c9c